# Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)

> **NCT05682326** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 4 (actual)

## Conditions studied

- Anaemia

## Interventions

- **DRUG:** Daprodustat

## Key facts

- **NCT ID:** NCT05682326
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-06
- **Primary completion:** 2024-10-18
- **Final completion:** 2025-03-17
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05682326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05682326, "Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05682326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*